Peer Review reports
From: Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
| Original Submission | ||
|---|---|---|
| 28 Jun 2018 | Submitted | Original manuscript |
| 13 Aug 2018 | Reviewed | Reviewer Report - Gabor Nemeth |
| 17 Aug 2018 | Reviewed | Reviewer Report - Takahiko Hayashi |
| 26 Oct 2018 | Author responded | Author comments - Patrick R Merz |
| Resubmission - Version 2 | ||
| 26 Oct 2018 | Submitted | Manuscript version 2 |
| 15 Nov 2018 | Reviewed | Reviewer Report - Gabor Nemeth |
| 15 Nov 2018 | Reviewed | Reviewer Report - Takahiko Hayashi |
| 20 Nov 2018 | Author responded | Author comments - Patrick R Merz |
| Resubmission - Version 3 | ||
| 20 Nov 2018 | Submitted | Manuscript version 3 |
| Publishing | ||
| 27 Nov 2018 | Editorially accepted | |
| 11 Dec 2018 | Article published | 10.1186/s12886-018-0978-9 |
You can find further information about peer review here.